Nurix Therapeutics, Inc. (NRIX) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
08M15M22M30M38M45M52M60MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
01020304050607080Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-200M-175M-150M-125M-100M-75M-50M-25M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-100-62-25125088125162200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income Variation
03875112150188225262300Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-80-2040100160220280340400Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-7-6-5-4-3-2-101Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
02M5M8M10M12M15M18M20MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
038M75M112M150M188M225M262M300MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
038M75M112M150M188M225M262M300MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics